TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05636449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Suprainguinal fascia iliaca block
Description: After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Periarticular Infiltration
Description: A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
Study: NCT04976907

Intervention type: DEVICE
Intervention: Contactless vital sign information collection
Description: Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
Study: NCT06048640

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dynamine (methylliberine)
Description: Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dynamine (methylliberine)
Description: Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
Study: NCT04768608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1-PSMA-CART cells
Description: PD1-PSMA-CART cells will be given IV at split doses
Study: NCT04600661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise therapy
Description: Neuromuscular training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise therapy
Description: Neuromuscular training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise therapy
Description: Neuromuscular training
Study: NCT05435443

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PowerBreathe and PEP Therosold tools
Description: Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe and PEP Therosold tools
Description: Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM.
Study: NCT05844488

Intervention type: DEVICE
Intervention: PrecivityAD
Description: Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
Study: NCT04579939

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Candy Glucose Tolerance Test
Description: Participants will use a popular dextrose candy alternative to help assess glycemic response.
Study: NCT05097040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT)
Description: The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
Study: NCT06293651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4505
Description: Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4505 + Pembrolizumab
Description: Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
Study: NCT04980144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% hyaluronate
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study: NCT06050824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparing Load and Concomitant therapy
Description: Levofloxacin - Omeprazole - nitazoxanide - doxycycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparing Load and Concomitant therapy
Description: Levofloxacin - Omeprazole - nitazoxanide - doxycycline
Study: NCT04392180

Intervention type: OTHER
Intervention: Qualitative Interview
Description: There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
Study: NCT04823299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Cryoballoon pulmonary vein isolation ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation +EPS guided trigger and substrate ablation
Description: RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
Study: NCT05053165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-P6
Description: Healthy subjects will be randomized to receive LB-P6 once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-P8
Description: Healthy subjects will be randomized to receive LB-P8 once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy subjects will be randomized to receive placebo once daily orally
Study: NCT04991779

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-assisted cEEG detection tool
Description: This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association.
Study: NCT06393088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IR REHAB
Description: Participants undergo therapy sessions with active, dual frequency, low level laser therapy device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants undergo therapy sessions with disabled device producing no laser energy
Study: NCT04894747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bolus ingestion of protein
Description: Ingestion of 25g of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bolus ingestion of protein
Description: Ingestion of 25g of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bolus ingestion of protein
Description: Ingestion of 25g of protein
Study: NCT05090657

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Description: After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
Study: NCT05417425

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant
Description: The three omeza products were designed to be used in combination for the treatment of chronic wounds
Study: NCT05833386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral access sheath placement during flexible ureteroscope for renal stones
Description: Ureteral access sheath placement during flexible ureteroscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral access sheath placement during flexible ureteroscope for renal stones
Description: Ureteral access sheath placement during flexible ureteroscope
Study: NCT06021821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoundMind App
Description: he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spotify Playlist
Description: Participants will listen to a calm vibes playlist by Spotify.
Study: NCT06150326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical honey Activon® 25g Tube
Description: no blinding procedures will be set up for the adminisration of the treatement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: no blinding procedures will be set up for the adminisration of the treatement
Study: NCT06056869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Description: will be given during first stage of labor intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo
Study: NCT06202716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab plus CapeOX chemotherapy
Description: Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
Study: NCT04806308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otolaryngology stretching micro-breaks (OSMB)
Description: Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
Study: NCT04548453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uterine electromyography
Description: Multichannel uterine electromyography will record uterine biosignals during labor.
Study: NCT05571878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog
Description: All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
Study: NCT04700826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants
Description: choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
Study: NCT04853459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Border modeling..Measurement
Description: By using light cure to make border modeling in complete denture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Border modeling..Measurement
Description: By using light cure to make border modeling in complete denture.
Study: NCT03884166

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoscopy
Description: Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoscopy
Description: Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
Study: NCT06114706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physicians assess patients
Description: Physicians are asked to assess patients following the current Swedish guideline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurses assess patients
Description: Nurses are asked to assess patients following the current Swedish guideline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacists assess patients
Description: Pharmacists are asked to assess patients following the current Swedish guideline
Study: NCT05265806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral oxytocin
Description: Each subject will be assigned to administration of oxytocin lingual spray (24 IU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
Study: NCT04768179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
Description: Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
Description: Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
Study: NCT05007795

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted sequencing using the GenoScreen Deeplex assay
Description: Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
Study: NCT05719090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
Study: NCT05915702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05451030

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remote ischemic preconditioning
Description: The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
Study: NCT05067647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENSEAL X1 Curved Jaw Tissue Sealer
Description: ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
Study: NCT05939180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
Study: NCT05669768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib/Tamoxifen
Description: Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
Study: NCT05184842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
Study: NCT05354232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
Study: NCT05064462

Intervention type: OTHER
Intervention: Collection of EDTA blood sample (5 to 7 ml)
Description: For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care.
Study: NCT03734497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Carotis FTc 500 ml Ringer's lactate Lafleks®
Description: will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Preloading 10 ml/kg Ringer's lactate Lafleks®
Description: will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Control 2 ml/kg Ringer's lactate Lafleks®
Description: will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia
Study: NCT05488548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP31670
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP31670
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP31670
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.